Prostate Cancer Therapy Aftercare Guidance Varies
Patients receiving Lu-177 PSMA radioligand therapy may receive inconsistent instructions on protecting family members after treatment.
Updated on Nov. 5, 2026 in Cancer
Live Poll
Do you trust doctors to give clear guidance on safely caring for family after treatment?
An international survey of 102 centers across 23 countries found that guidance given to patients after Lu-177 PSMA radioligand therapy varies widely, particularly on radiation precautions around family members. Researchers also developed a structured patient information template to standardize that guidance for patients receiving the treatment.
Why it matters
Patients remain radioactive after Lu-177 PSMA therapy, so clear discharge instructions matter for protecting family members, especially children and pregnant women. The findings show that many centers lack consistent, formal guidance, which is why researchers published a template to help standardize it.
The study is a 152-question international survey of 186 centers known to offer Lu-177 PSMA therapy, with 102 centers from 23 countries on five continents responding between January and October 2025. Recommended separation distances ranged from one to three meters, and some outpatient sites specified maintenance periods of one to three days while others specified up to seven days, but the survey did not measure patient outcomes.
The players
Journal of Nuclear Medicine
A peer-reviewed journal of the Society of Nuclear Medicine and Molecular Imaging that publishes research on the use of radioactive agents in diagnosing and treating diseases, including cancer.
The details
Lu-177 PSMA therapy uses a radioactive compound that binds to prostate-specific membrane antigen on cancer cells, delivering radiation directly to the tumor. Because the radioactive material is excreted over time, patients can emit radiation for a period after leaving the clinic. The survey covered pretreatment preparation, the therapy itself, radiation precautions, and posttreatment procedures, with separate questions for inpatient and outpatient settings. Nearly all responding centers imposed no fasting requirements and allowed patients to continue their regular medications.
Timeline
January 2025: Web-based survey distributed to 186 centers.
October 2025: Survey closed.
November 5, 2026: Study published in the Journal of Nuclear Medicine.
Health Landscape
Lu-177 PSMA therapy has become an established option for advanced prostate cancer, and its wider adoption across many countries has made consistent aftercare guidance a growing practical priority. This survey documents the variation in that guidance across centers worldwide, and the proposed template is an early attempt to standardize it alongside existing national regulations.
If you or a family member is preparing for or recovering from this therapy, it is worth asking your care team specifically what radiation precautions apply at home, including how long to keep distance from children and pregnant household members. Patients receiving outpatient treatment should confirm they have written discharge instructions before leaving the clinic.
The takeaway
Clear, written aftercare instructions are an important part of radioligand therapy, and the protective guidance you receive should be specific about distance and duration. Ask your oncology team to confirm these details in writing before you go home.
Further reading
For more background on treatment approaches, explore our Cancer coverage.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Do you trust doctors to give clear guidance on safely caring for family after treatment?
